GENE ONLINE|News &
Opinion
Blog

Roche
Roche Buys Good Therapeutics For $250 Million Upfront, Obtains Immune Stimulating Antibody Conjugate Program
2022-09-08
Roche Dives Deeper into Off-The-Shelf Cell Therapies in Poseida Partnership
2022-08-04
Cancer Immunotherapy Phase III Trial Yields Positive Results
2022-08-02
Roche Bags Fast Track Label for New Alzheimer’s Diagnostic
2022-07-21
Roche Offers Up to $1 Billion for Avista to Develop Eye Disease Vectors
2022-07-20
Roche Receives Rights to Ionis’ Antisense Kidney Disease Drug for $55 Million
2022-07-12
Roche’s Non-Hodgkin Lymphoma Drug Could See Accelerated Approval By December
2022-07-07
Europe Okays Roche’s CAR-T Competitor for Blood Cancer
2022-06-09
First Oral SMA Drug by Roche Now Available to Newborns
2022-06-01
These Companies Are Harnessing Oncolytic Viruses to Target Cancer
2022-05-25
Roche’s Phase III Trial of ES-SCLC Immunotherapy Fails to Extend Progression-Free Survival
2022-04-05
The Lancet Publishes Data on Roche’s Long-Lasting Bispecific Antibody for Vision Loss
2022-01-25
With A New Medical Device and Accompanying Platform, Roche Advances its Digital Ecosystem
2022-01-14
JPM22 Highlights: Amgen Sees Potential in Arrakis, Freenome Gets Boosted by Roche Again
2022-01-12
Roche Looks for Peptide-Like Small Molecules with Prism BioLab, joining Merck, Eisai and Boehringer Ingelheim
2022-01-05
1 2 3 5
LATEST
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
2022-09-27
Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics
2022-09-27
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
2022-09-27
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
2022-09-26
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
2022-09-26
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!